140 related articles for article (PubMed ID: 9792383)
1. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group.
Hughes MD; Daniels MJ; Fischl MA; Kim S; Schooley RT
AIDS; 1998 Oct; 12(14):1823-32. PubMed ID: 9792383
[TBL] [Abstract][Full Text] [Related]
2. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group.
AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1123-33. PubMed ID: 10954887
[TBL] [Abstract][Full Text] [Related]
3. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
Chang LW; Harris J; Humphreys E
Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
[TBL] [Abstract][Full Text] [Related]
4. The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Montaner JS; DeMasi R; Hill AM
AIDS; 1998 Mar; 12(5):F23-8. PubMed ID: 9543436
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
Phillips AN; Eron JJ; Bartlett JA; Rubin M; Johnson J; Price S; Self P; Hill AM
AIDS; 1996 Jul; 10(8):859-65. PubMed ID: 8828743
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis for the evaluation of potential surrogate markers.
Daniels MJ; Hughes MD
Stat Med; 1997 Sep; 16(17):1965-82. PubMed ID: 9304767
[TBL] [Abstract][Full Text] [Related]
7. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
Seminari E; De Silvestri A; Boschi A; Tinelli C
AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
[TBL] [Abstract][Full Text] [Related]
8. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Phillips AN; Eron J; Bartlett J; Kuritzkes DR; Johnson VA; Gilbert C; Johnson J; Keller A; Hill AM
AIDS; 1997 Feb; 11(2):169-75. PubMed ID: 9030363
[TBL] [Abstract][Full Text] [Related]
9. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors.
Staszewski S; DeMasi R; Hill AM; Dawson D
AIDS; 1998 Oct; 12(15):1991-7. PubMed ID: 9814867
[TBL] [Abstract][Full Text] [Related]
11. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
[TBL] [Abstract][Full Text] [Related]
12. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis.
Mills EJ; Kelly S; Bradley M; Mollon P; Cooper C; Nachega J
HIV Med; 2008 Nov; 9(10):849-57. PubMed ID: 18795965
[TBL] [Abstract][Full Text] [Related]
14. Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.
Chêne G; Binquet C; Moreau JF; Neau D; Pellegrin I; Malvy D; Ceccaldi J; Lacoste D; Dabis F
AIDS; 1998 Dec; 12(17):2313-20. PubMed ID: 9863874
[TBL] [Abstract][Full Text] [Related]
15. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
Kim S; Hughes MD; Hammer SM; Jackson JB; DeGruttola V; Katzenstein DA
AIDS Res Hum Retroviruses; 2000 May; 16(7):645-53. PubMed ID: 10791875
[TBL] [Abstract][Full Text] [Related]
16. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.
Miller V; Mocroft A; Reiss P; Katlama C; Papadopoulos AI; Katzenstein T; van Lunzen J; Antunes F; Phillips AN; Lundgren JD
Ann Intern Med; 1999 Apr; 130(7):570-7. PubMed ID: 10189326
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected infants and children.
Palumbo PE; Raskino C; Fiscus S; Pahwa S; Fowler MG; Spector SA; Englund JA; Baker CJ
JAMA; 1998 Mar; 279(10):756-61. PubMed ID: 9508151
[TBL] [Abstract][Full Text] [Related]
18. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
19. From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis.
Song A; Liu X; Huang X; Meyers K; Oh DY; Hou J; Xia W; Su B; Wang N; Lu X; Xia H; Yang X; Chen H; Wu H
Front Immunol; 2018; 9():212. PubMed ID: 29487595
[TBL] [Abstract][Full Text] [Related]
20. Markers of HIV infection in the Concorde trial. Concorde Co-ordinating Committee.
Walker AS; Peto TE; Babiker AG; Darbyshire JH
QJM; 1998 Jun; 91(6):423-38. PubMed ID: 9709461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
